Tyra Biosciences, Inc. (TYRA) · Sep 14, 2026 · Share issuance

Tyra Biosciences prices $400M equity raise as pivotal trial work accelerates

$400M equity raise — ~18.2M shares and pre-funded warrants; $400M gross proceeds

Tyra secures $400 million for its FGFR pipeline, but the raise adds roughly 18.2 million shares and warrants to the capital base.

Tyra is a clinical-stage biotech advancing FGFR-targeted medicines, with oral dabogratinib moving through Phase 2 studies in bladder cancer and pediatric skeletal dysplasia. The company had recently said its $353.9 million cash, cash equivalents and marketable securities could fund operations into the second half of 2028, while initial SURF302 data had become an immediate development milestone.

The filing materially strengthens funding, but it is not free capital. Tyra priced an underwritten offering of 9,079,000 common shares plus pre-funded warrants for another 9,078,529 shares, targeting approximately $400.0 million of gross proceeds.

MeasureFiling figureComparison
Common shares sold9.079 million$22.03 per share
Pre-funded warrant shares9.079 million$22.029 per warrant; $0.001 exercise price
Total potential shares issued18.158 millionVersus 59.663 million common shares outstanding at June 30, 2026
Gross proceeds$400.0 millionBefore discounts, commissions and expenses
Expected closingSeptember 15, 2026Subject to customary conditions

The size is the real signal. Relative to the 59.7 million common shares outstanding at June 30, the offering represents roughly 30% additional share-equivalent issuance before considering other dilution. The pre-funded warrants are economically close to shares because they are immediately exercisable at a nominal price and do not expire.

This appears designed to fund a broader clinical push rather than solve an immediate liquidity problem. Tyra already had a stated runway into the second half of 2028, so the raise likely gives the company more flexibility to advance multiple programs, absorb rising trial costs and reduce dependence on another near-term financing. That benefit is balanced by substantial dilution, and the filing does not disclose a new clinical result or a change to the underlying probability of success. The recent ATM expansion made additional equity financing partly foreseeable, but this $400 million underwritten transaction is materially larger than that previously disclosed capacity.

Bottom line: This is a meaningful balance-sheet event, not a clinical validation event. Tyra buys considerable development flexibility ahead of its pipeline milestones, but shareholders pay for it through a large new share-equivalent issuance.

What to watch next

Offering close, September 15, 2026

Original filing on SEC EDGAR

More Tyra Biosciences, Inc. news

Tyra Biosciences prices $400M equity raise as pivotal trial work accelerates | TYRA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.